用于患有慢性支性肺病的儿童的粘结剂
Hannah E O'Farrell1,2, Esther R McElrea1, Anne B Chang1,2,3
1Australian Centre for Health Services Innovation and School of Clinical Medicine, Queensland University of Technology, Brisbane, Australia.
The Cochrane database of systematic reviews
|March 28, 2025
概括
粘结剂可以减少患有慢性支性肺病 (CSLD) 的儿童的呼吸道恶化. 然而,证据有限,需要进一步的研究来确认CSLD治疗的益处和安全性.
科学领域:
- 儿科肺病学 儿科肺病学
- 呼吸系统医学 呼吸系统医学
- 基于证据的医学基于证据的医学.
背景情况:
- 慢性支性肺病 (CSLD) 包括支气管支障碍和长期细菌支气管炎 (PBB) 等疾病,其特点是慢性生产性咳.
- 对儿童的CSLD新的治疗策略是研究的首要任务.
- 粘结剂旨在增强粘膜清除,可能打破呼吸道感染和炎症的循环.
研究的目的:
- 评估粘膜消毒药在减少恶化和改善CSLD儿童 (包括PBB和支气管切除症) 的生活质量的有效性.
- 评估与儿科CSLD的粘结剂使用相关的安全性和不良事件的风险.
主要方法:
- 进行了随机对照试验 (RCT) 的系统审查,搜索主要数据库,直到2024年9月.
- 包括涉及儿童 (≤18岁) 患有CSLD的研究,比较粘菌剂与安慰剂或无干预.
- 数据提取和质量评估使用了Cochrane风险偏差工具 (RoB 2) 和GRADE标准;结果包括恶化率,肺功能 (FEV1,FVC),生活质量和不良事件.
主要成果:
- 只有一个RCT符合纳入标准,涉及52名患有非囊性纤维化支气管切除症的儿童,将 nebulized hypertonic盐水与单独物理治疗进行比较.
- 干预组的呼吸道恶化率显著降低 (2.50比7.80每儿童年),FEV1和FVC的改善更大.
- 证据质量非常低,没有关于生活质量或不良事件的数据;这项研究被认为具有高偏差风险.
结论:
- 目前来自单一的高风险偏差研究的证据不足以证实 nebulized 过敏盐水在减少恶化或改善稳定儿科CSLD的肺功能方面的益处.
- 进一步高质量,多中心的RCT和更长的持续时间是必要的,以调查儿童CSLD的各种粘菌剂.
- 目前对高血压盐水和口服埃尔多斯的研究可能会在未来的审查中提供更明确的证据.
相关概念视频
Drugs Used in Upper Respiratory Disorders: Overview
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...


